Literature DB >> 30527433

Update on the epidemiology, risk factors, and disease outcomes of psoriatic arthritis.

Dilek Solmaz1, Lihi Eder2, Sibel Zehra Aydin3.   

Abstract

Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects different structures of the musculoskeletal system in addition to the skin and the nail. The complexity of the disease had been a barrier to understand the pathogenesis and define valid outcome tools; however, our understanding about the disease has considerably increased with time mainly because of the advances in imaging, new discoveries in genetics and underlying inflammatory pathways, and better understanding of the epidemiology of the disease and environmental risk factors. The purpose of this review is to summarize developments and changes in epidemiology, risk factors for developing PsA, and outcome measures with a focus on data obtained in the last 10 years.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Epidemiology; Outcome measures; Psoriatic arthritis; Risk factors

Mesh:

Year:  2018        PMID: 30527433     DOI: 10.1016/j.berh.2018.09.006

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  5 in total

1.  Patient characteristics and minimal disease activity in psoriatic arthritis: a transcontinental comparison.

Authors:  Sibel Bakirci; Gizem Ayan; Ummugulsum Gazel; Ilaria Tinazzi; Dilek Solmaz; Esen Kasapoglu; Umut Kalyoncu; Sibel Zehra Aydin
Journal:  Clin Rheumatol       Date:  2021-02-17       Impact factor: 2.980

Review 2.  Late-Onset and Elderly Psoriatic Arthritis: Clinical Aspects and Management.

Authors:  Francesco Caso; Marco Tasso; Maria Sole Chimenti; Luca Navarini; Carlo Perricone; Nicolò Girolimetto; Rosario Peluso; Antonio Del Puente; Antonella Afeltra; Roberto Perricone; Leonardo Punzi; Raffaele Scarpa; Luisa Costa
Journal:  Drugs Aging       Date:  2019-10       Impact factor: 3.923

3.  TOFA-PREDICT study protocol: a stratification trial to determine key immunological factors predicting tofacitinib efficacy and drug-free remission in psoriatic arthritis (PsA).

Authors:  Nienke J Kleinrensink; Frank T Perton; Juliëtte N Pouw; Nanette L A Vincken; Sarita A Y Hartgring; Mylène P Jansen; Saeed Arbabi; Wouter Foppen; Pim A de Jong; Janneke Tekstra; Emmerik F A Leijten; Julia Spierings; Floris P J G Lafeber; Paco M J Welsing; Marloes W Heijstek
Journal:  BMJ Open       Date:  2022-10-10       Impact factor: 3.006

Review 4.  Clinical, laboratory, and genetic markers for the development or presence of psoriatic arthritis in psoriasis patients: a systematic review.

Authors:  Michelle L M Mulder; Tamara W van Hal; Mark H Wenink; Hans J P M Koenen; Frank H J van den Hoogen; Elke M G J de Jong; Juul M P A van den Reek; Johanna E Vriezekolk
Journal:  Arthritis Res Ther       Date:  2021-06-14       Impact factor: 5.156

5.  Trends in psoriatic arthritis epidemiology in Poland.

Authors:  Małgorzata Tłustochowicz; Waldemar Wierzba; Michał Marczak; Witold Tłustochowicz; Andrzej Śliwczyński; Filip Raciborski; Brygida Kwiatkowska; Melania Brzozowska; Andrzej Jacyna; Bartłomiej Kisiel
Journal:  Rheumatol Int       Date:  2020-10-28       Impact factor: 2.631

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.